| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 05/27/2004 | WO2004043457A1 Cholesterol absorptions inhibitors for the treatment of autoimmune disorders |
| 05/27/2004 | WO2004043456A1 Cholesterol absorption inhibitors for the treatment of demyelination |
| 05/27/2004 | WO2004043454A1 Acetyl-l-carnitine for the prevention and/or treatment of peripheral neuropathies induced by anticancer agents |
| 05/27/2004 | WO2004043226A2 Methods for predicting whether subjects with mild cognitive impairment (mci) will develop alzheimer's disease |
| 05/27/2004 | WO2004033456A3 1,4-diazabicyclo[3.2.2]nonanecarboxamide derivatives, preparation and therapeutic use thereof related to malfunction of nicotinic receptors |
| 05/27/2004 | WO2004029019A3 Compounds for the treatment of alzheimer’s disease |
| 05/27/2004 | WO2004028521A3 Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders |
| 05/27/2004 | WO2004016583A8 Substituted glycine derivatives for use as medicaments |
| 05/27/2004 | WO2004014881A3 '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5 |
| 05/27/2004 | WO2004009762A3 Flea and tick octopamine receptor nucleic acid molecules, proteins and thereof |
| 05/27/2004 | WO2003088908A3 Heterocyclo inhibitors of potassium channel function |
| 05/27/2004 | WO2003081258A3 Diagnostics and therapeutics for diseases associated with growth hormone secretagogue receptor (ghs) |
| 05/27/2004 | WO2003073986A3 Aminoalkylphosphonates and related compounds as edg receptor agonists |
| 05/27/2004 | WO2003070245B1 Mono-ester and asymmetrically substituted di-ester pro-drugs of the dopamine d1 receptor agonists |
| 05/27/2004 | WO2003059276B1 Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof |
| 05/27/2004 | WO2003031436A8 Heterocyclic compounds for use in the treatment of disorders of the urinary tract |
| 05/27/2004 | WO2003025177A3 Sequences involved in phenomena of tumour suppression, tumour reversion, adoptosis and/or resistance to viruses and the use thereof as medicaments |
| 05/27/2004 | WO2003011262A3 Use of 2-alkoxyphenyl-substituted imidazotriazinones for the treatment of diseases associated with cgmp regulated processes |
| 05/27/2004 | WO2003004604A3 Phage displayed pdz domain ligands |
| 05/27/2004 | WO2003002109A3 Use of tyrosine kinase inhibitors for treating autoimmune diseases |
| 05/27/2004 | WO2002090375A8 Liver x receptor agonists |
| 05/27/2004 | WO2002072088A3 Modulators of kcnq potassium channels and use thereof in treating migraine and mechanistically related diseases |
| 05/27/2004 | WO2002065977A8 Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof |
| 05/27/2004 | WO2002060480A9 Methods for treating or preventing skin disorders using cd2-binding agents |
| 05/27/2004 | WO2000073764A3 Composition and methods for the therapeutic use of an atonal-associated sequence |
| 05/27/2004 | WO1999046281A8 Novel polypeptides and nucleic acids encoding the same |
| 05/27/2004 | US20040102634 For therapy and prophylaxis of hyperglycemia, hyperlipemia and inflammatory disease |
| 05/27/2004 | US20040102633 For therapy and prophylaxis of chronic obstructive pulmonary disease (COPD), asthma, airway hyper- reactivity, cough; inflammatory diseases such as inflammatory bowel disease, psoriasis, fibrositis, osteoarthritis |
| 05/27/2004 | US20040102630 For therapy of cancer, auto-immune diseases, cardiovascular diseases, infectious diseases, nephrological diseases, neurodegenerative diseases and viral infections |
| 05/27/2004 | US20040102626 Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines with adenosine receptor-binding activity and their use cardiovascular preparations |
| 05/27/2004 | US20040102613 For prophylactic/therapeutic drugs for heart/central nervous system diseases; diagnostic kits |
| 05/27/2004 | US20040102609 Peptide-containing alpha-ketoamide cysteine and serine protease inhibitors |
| 05/27/2004 | US20040102527 Use of cyclohexenone derivatives in the manufacture of a medicament for treating diabetic complications |
| 05/27/2004 | US20040102523 Modafinil polymorphic forms |
| 05/27/2004 | US20040102512 Statins reduce or repress T-lymphocyte activation mediated by MHC class II or CD40; new target is alternative to cytokine inhibitors |
| 05/27/2004 | US20040102508 Naphathalene derivatives which bind to the ep4 receptor |
| 05/27/2004 | US20040102507 Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods |
| 05/27/2004 | US20040102506 Pyrazole compositions useful as inhibitors of ERK |
| 05/27/2004 | US20040102498 Estrogen receptor modulators |
| 05/27/2004 | US20040102496 Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases |
| 05/27/2004 | US20040102481 Benzenesulfonic acid indol-5-yl esters as antagonists of the 5-ht6 receptor |
| 05/27/2004 | US20040102478 Alzheimer's and Parkinson's disease; antiinflamamtory agents; antiallergens; vision defects |
| 05/27/2004 | US20040102474 Dietetics; antidiabetic agents; eating disorders |
| 05/27/2004 | US20040102471 Viricides; anticancer agents |
| 05/27/2004 | US20040102468 Controlling discharge of urine |
| 05/27/2004 | US20040102467 Antiinflammatory agents; central nervous system disorders; antiproliferative agents |
| 05/27/2004 | US20040102464 Hypotensive agents; cardiovascular disorders; anticancer agents; headaches; antihistamines; antiinflamamtory agents |
| 05/27/2004 | US20040102460 Phosphodiesterase 4 inhibitors |
| 05/27/2004 | US20040102459 Central nervous system disorders; Parkinson's disease; antidepressants |
| 05/27/2004 | US20040102457 Central nervous system disorders; anxiolytic agents; antidepressants; attention deficit disorders; Alzheimer's diseases |
| 05/27/2004 | US20040102455 Autoimmune diseases; antiinflammatory agents; antiallergens; viricides; anticancer agents |
| 05/27/2004 | US20040102451 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| 05/27/2004 | US20040102450 Substituted oxoazaheterocyclyl compounds |
| 05/27/2004 | US20040102447 7-amino-2-alkylthiopteridin-4-yl-amines for the treatment of chemokine-related diseases |
| 05/27/2004 | US20040102442 Central nervous system disorders; brain disorders |
| 05/27/2004 | US20040102441 Ortho-substituted anthranilic acid amides and their use as medicaments |
| 05/27/2004 | US20040102440 Method of promoting smoking cessation |
| 05/27/2004 | US20040102438 Gaba-receptor modulators for the treatment of neurodegenerative diseases of the eye |
| 05/27/2004 | US20040102435 Alzheimer's disease; psychological disorders; anxiolytic agents; antidepressants; hormone replacement therapy |
| 05/27/2004 | US20040102434 Method for treating pain with loxapine and amoxapine |
| 05/27/2004 | US20040102428 Chemokine receptor binding heterocyclic compounds |
| 05/27/2004 | US20040102418 Compounds for the treatment of inflammatory disorders |
| 05/27/2004 | US20040102414 Methods and compositions for treating flaviviruses and pestiviruses |
| 05/27/2004 | US20040102408 Method and medicament for inhibiting the expression of a given gene |
| 05/27/2004 | US20040102379 Fibroblast growth factor homologous factors (FHFs) and methods of use |
| 05/27/2004 | US20040102376 Use of rgm and its modulators |
| 05/27/2004 | US20040102370 Peptides that stimulate cell survival and axon regeneration |
| 05/27/2004 | US20040101934 Beverage comprising peptide nerve growth factor conjugate for use in treatment of pain; analgesics; tranquilizers |
| 05/27/2004 | US20040101882 Secreted proteins |
| 05/27/2004 | US20040101579 Isoflavones and saponins in defined ratios, menopause, cancer |
| 05/27/2004 | US20040101551 Transdermal therapeutic system for releasing venlafaxine |
| 05/27/2004 | US20040101550 Transdermal therapeutic system |
| 05/27/2004 | US20040101529 Regulation of human serine-threonine protein kinase |
| 05/27/2004 | US20040101517 Central nervous system diosrders; Alzheimer's disease; Parkinson's disease; regeneration normal endothelial function; applying oxidation stresses to cells; angiotensin receptor antagonist |
| 05/27/2004 | US20040101509 Chemokine mutants in the treatment of multiple sclerosis |
| 05/27/2004 | US20040101481 Inhalation therapy |
| 05/27/2004 | DE10252667A1 New spiro-((cyclohexane)-tetrahydropyrano-(3,4-b)-indole) derivatives, are ORL1 receptor ligands useful e.g. for treating anxiety, depression, epilepsy, senile dementia, withdrawal symptoms or especially pain |
| 05/27/2004 | DE10252650A1 New 1,4-disubstituted cyclohexylamine derivatives, are opioid receptor like-receptor 1 receptor ligands useful e.g. for treating anxiety, depression, epilepsy, senile dementia, withdrawal symptoms or especially pain |
| 05/27/2004 | CA2765093A1 Bicyclic-substituted amines as histamine-3 receptor ligands |
| 05/27/2004 | CA2509252A1 Synergistic combinations with analgesic properties comprising n-acylated 4-hydroxyphenylamine derivatives |
| 05/27/2004 | CA2505372A1 Fused heterocyclic compounds |
| 05/27/2004 | CA2505355A1 Methods for predicting whether subjects with mild cognitive impairment (mci) will develop alzheimer's disease |
| 05/27/2004 | CA2505249A1 N-sulfonylaminothiazole |
| 05/27/2004 | CA2504959A1 Substituted alkyl-pyridazinones for the treatment of memory and learning malfunctions |
| 05/27/2004 | CA2504916A1 Cholesterol absorptions inhibitors for the treatment of autoimmune disorders |
| 05/27/2004 | CA2504878A1 Cholesterol absorption inhibitors for the treatment of demyelination |
| 05/27/2004 | CA2504737A1 Aromatic sulfone hydroxamic acids and their use as protease inhibitors |
| 05/27/2004 | CA2503993A1 Novel 2,3-dihydro-4(1h)-pyridinone derivatives, method for production thereof and pharmaceutical composition comprising the same |
| 05/27/2004 | CA2503992A1 Novel phenylnaphthalene derivatives, method for production thereof and pharmaceutical compositions comprising the same |
| 05/26/2004 | EP1422524A1 Screening method |
| 05/26/2004 | EP1422240A2 Analogs of nociceptin |
| 05/26/2004 | EP1422230A1 Novel ester derivatives of buprenorphine and their preparation processes, and long acting analgestic pharmaceutical compositions |
| 05/26/2004 | EP1422217A2 Aminocyclohexyl ether compounds and uses thereof |
| 05/26/2004 | EP1421955A1 Percutaneous absorption preparations |
| 05/26/2004 | EP1421948A2 Use of botulinum toxins for treating sweating in humans |
| 05/26/2004 | EP1421943A1 Use of low-molecular-weight heparins for preventing and treating central nervous system trauma |
| 05/26/2004 | EP1421942A1 Use of glycyrrhizin and its derivatives as RANTES inducers |
| 05/26/2004 | EP1421936A1 Potassium channel opener |
| 05/26/2004 | EP1421391A2 Sodium channel regulators and modulators |
| 05/26/2004 | EP1421377A2 The natural ligand for orphan g protein coupled receptor gpr86 and methods of use |